IMRX Immuneering Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMRX

Price (delayed)

$5.15

Market cap

$333.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$295.5M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10
Highlights
The EPS has soared by 51% year-on-year and by 12% since the previous quarter
The debt has declined by 9% year-on-year and by 2.6% since the previous quarter
The net income has increased by 8% year-on-year but it has declined by 5% since the previous quarter
The quick ratio has decreased by 41% from the previous quarter
Immuneering's equity has decreased by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://immuneering.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of IMRX

IMRX stock price

How has the Immuneering stock price performed over time
Intraday
-1.53%
1 week
-3.38%
1 month
19.21%
1 year
-13.01%
YTD
-21.73%
QTD
3.21%

Financial performance

How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.47M
Net income
-$57.28M
Gross margin
N/A
Net margin
N/A
The net income has increased by 8% year-on-year but it has declined by 5% since the previous quarter
The operating income has declined by 7% since the previous quarter

Price vs fundamentals

How does IMRX's price correlate with its fundamentals

Growth

What is Immuneering's growth rate over time

Valuation

What is Immuneering stock price valuation
P/E
N/A
P/B
1.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 51% year-on-year and by 12% since the previous quarter
IMRX's P/B is 13% less than its 5-year quarterly average of 2.0 but 9% more than its last 4 quarters average of 1.6
Immuneering's equity has decreased by 8% from the previous quarter

Efficiency

How efficient is Immuneering business performance
IMRX's return on invested capital has surged by 93% year-on-year and by 33% since the previous quarter
The ROE has soared by 81% YoY and by 15% from the previous quarter
The ROA has soared by 78% year-on-year and by 14% since the previous quarter

Dividends

What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMRX.

Financial health

How did Immuneering financials performed over time
The quick ratio has decreased by 41% from the previous quarter
The current ratio has declined by 40% since the previous quarter
The debt is 98% smaller than the equity
IMRX's debt to equity has dropped by 86% year-on-year
The debt has declined by 9% year-on-year and by 2.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.